PLoS ONE · 2016 · 98 citations · 25 references
MedicineBiochemistryOncologyCancer ScreeningMolecular DiagnosticsMolecular PathologyCancer BiomarkersCancer Molecular DiagnosticsHepatic Function TestingLiver Function TestsPlasma ProteinsTumor MarkersAlpha-fetoprotein BiomarkerBiomarker PanelsComparative Diagnostic PerformanceDiagnostic Performance MetricsHepatocellular Injury BiomarkersPlasma In Liver DiseasePlasma Protein AnalysisSensitivity
BACKGROUND & AIMS: Alpha-fetoprotein (AFP) is the most widely used serum biomarker for hepatocellular carcinoma (HCC), despite its limitations. As complementary biomarkers, protein induced by vitamin K absence (PIVKA-II), osteopontin (OPN), and Dickkopf-1 (DKK-1) have been proposed. This study aimed to perform a head-to-head comparison of the diagnostic performance of AFP, PIVKA-II, OPN and DKK-1 as single or in combination to seek the best biomarker or panel, and to investigate the clinical factors affecting their performance. METHODS: Using 401 stored plasma samples obtained from 208 HCC patients and 193 liver cirrhosis control patients, plasma AFP, PIVKA-II, OPN and DKK-1 levels were measured by ELISA, and receiver operating characteristic curve analyses were performed for each biomarker and for every combination of two to four markers. RESULTS: Of the four biomarkers, AFP showed the highest area under the curve (0.786). The sensitivity and specificity for each single biomarker was 62% and 90.2% (AFP>20 ng/mL), 51.0% and 91.2% (PIVKA-II>10 ng/mL), 46.2% and 80.3% (OPN>100 ng/mL), and 50.0% and 80.8% (DKK-1>500 pg/mL), respectively. Among the combinations of two biomarkers, AFP>20 ng/mL or DKK-1>500 pg/mL showed the best diagnostic performance (sensitivity 78.4%, specificity 72.5%). Triple or quadruple combination did not improve the diagnostic performance further. The patient's age, etiology and tumor invasiveness of HCC affected the performance of each marker. CONCLUSIONS: AFP was the most useful single biomarker for HCC diagnosis, and the combined measurement of AFP and DKK-1 could maximize the diagnostic yield. Clinical decision should be based on the consideration of various factors affecting the diagnostic performance of each biomarker. Efforts to seek novel HCC biomarkers should be continued.
25
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay, Hai‐Rim Shin, Freddie Bray et al. · International Journal of Cancer · 2010 · 21.4K citations
Management of Hepatocellular Carcinoma: An Update Δσ
Jordi Bruix, Morris Sherman · Hepatology · 2011 · 8.1K citations · Full text
Reporting Recommendations for Tumor Marker Prognostic Studies
Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei et al. · Journal of Clinical Oncology · 2005 · 775 citations · Full text
Medicine, Biostatistics, Oncology +17